BACE1 and Cognitive impairment: If administered at a very early disease stage prior to the substantial accumulation of the Aβ-protein and loss of synapses, therapeutic intervention with BACE1-inhibition may well arrest the pathology progression and spare the patient from severe cognitive impairment.